Fig. 7: Low TSPAN6 expression is correlated with poor survival in human lung and pancreatic cancer patient survival with mesenchymal signatures. | Oncogene

Fig. 7: Low TSPAN6 expression is correlated with poor survival in human lung and pancreatic cancer patient survival with mesenchymal signatures.

From: TSPAN6 is a suppressor of Ras-driven cancer

Fig. 7: Low TSPAN6 expression is correlated with poor survival in human lung and pancreatic cancer patient survival with mesenchymal signatures.The alternative text for this image may have been generated using AI.

a TSPAN6 expression is significantly reduced in lung cancer (NSCLC) cancers from the GSE10245 cohort with an EMT signature ((NLCLC-EMT) versus an epithelial (NLCLCepith) signature (**p < 0.01)). The TSPAN6 probes used are indicated. b Low TSPAN6 expression levels (Affymetrix probes) predict poor overall survival of lung cancer patients from this cohort. Survival analysis was calculated using a log-rank test. Data presented were obtained using KM plotter. P values (log-rank test) and total numbers of patients with either low (black) or high (red) TSPAN6 expression are indicated. c TSPAN6 expression is significantly reduced in pancreatic adenocarcinoma (PDA) cancers with an EMT signature (PDA-exoc and PDA-QM) relative to those with an epithelial signature (PDA-epith) in the GSE17891 and GSE11838 cohorts. d Low TSPAN6 expression is correlated with poor survival in pancreatic ductal carcinoma patients from these cohorts (data presented as in b). Green bar-TSPAN6 low expression identifies PDA patients with advanced disease and early relapse with lethal outcome (18–24 months). NSCLCepith Non-Small Cell Lung Cancer epithelial subclass, NSCLCmes Non-Small Cell Lung Cancer mesenchymal subclass [36]; PDAepith Pancreatic Ductual Adenocarcinoma epithelial subclass, PDAexocrine Pancreatic Ductual Adenocarcinoma exocrine subclass, PDA-QM Pancreatic Ductual Adenocarcinoma quasi-mesenchymal subclass [37].

Back to article page